Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
Recruiting · NCT06482268 · Registry updated 2026-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) | Dyskinesias, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, atactic disorder, non-human animal, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 | 2026-08-17 | NCT06482268 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kyoto University | 9 |
| Sumitomo Pharma America, Inc. | 16 |
| Sumitomo Pharma Co., Ltd. | 2 |
| University of California, San Diego | 337 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Diego | La Jolla | United States | 25 |